Geron to Present at the BIO CEO & Investor Conference
MENLO PARK, Calif., February 8, 2010
- Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's product development programs at 10:30 a.m. EST on Tuesday, February 9, 2010, at the 12th Annual BIO CEO & Investor Conference in New York City.
The presentation will include updates on Geron's telomerase inhibitor drug (imetelstat sodium - GRN163L) and telomerase therapeutic vaccine (GRNVAC1) as well as the company's human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1), diabetes (GRNIC1), and osteoarthritis (GRNCHND1).
The webcast link for the live audio and slide presentation will be available at the following website address: http://www.veracast.com/webcasts/bio/ceoinvestor2010/94204495.cfm. The presentation will be archived for replay at the same address one hour after conclusion of the live event for a period of 30 days.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765 info@geron.com
